Written by HealthDay News
Updated on June 15, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, July 9, 2002 (HealthDayNews) -- African strains of HIV may be more resistant to current treatments than the forms found in North America and Western Europe.
"Although clinical studies are still very limited, early reports in the medical literature have suggested a poorer long-term response to antiviral therapies in African patients, despite a similar initial response," says Ernesto Freire, study author and a professor of biology and biophysics at Johns Hopkins University.
A subtype called HIV-B is most common in Western Europe and North America. However, two genetically different strains, HIV-A and HIV-C, are predominant in Africa.
Current therapies to treat HIV target HIV-B but may need to be altered to tackle the African subtypes, Freire says.
Compounds called protease inhibitors are among the most effective ways to combat HIV. The protease inhibitors help reduce the spread of the disease by binding to the HIV protease, a protein that's important in HIV reproduction.
In this study, published today in Biochemistry, Freire and his colleagues took a common HIV-B subtype mutation that could potentially be found in the African forms of the disease. The mutation creates drug resistance in HIV-B by enhancing the biochemical fitness of the protease.
The researchers introduced this mutation into HIV-A and HIV-C proteases. They found the resultant HIV-C and HIV-A proteases had biochemical fitness levels up to 1,000 times higher than that of normal HIV-B.
"In other words, the natural variations that exist in the protease of the African strains are not sufficient to cause resistance by themselves, but they amplify the effects of drug-resistant mutations and, hence, lead to a faster long-term failure of the therapy," Freire says.
He says this research shows HIV drug development needs to be broadened beyond targeting HIV-B.
There are more than 40 million people with HIV worldwide, and 70 percent of them are in Africa.
The World Bank offers a comprehensive roundup of the effects of AIDS on the continent of Africa.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.